tetano
Editor, Senior Moderator
Virus Res
. 2023 Jan 3;199039.
doi: 10.1016/j.virusres.2023.199039. Online ahead of print.
Lessons from resistance analysis in clinical trials of IV zanamivir
Phillip J Yates[SUP] 1 [/SUP], Nalini Mehta[SUP] 2 [/SUP], Helen A Watson[SUP] 3 [/SUP], Amanda F Peppercorn[SUP] 4 [/SUP]
Affiliations
Abstract
Influenza infection causes substantial morbidity and mortality during seasonal epidemics and pandemics. Antivirals, including neuraminidase inhibitors, play an important role in the treatment of severely ill patients infected with influenza. Resistance is a key factor that can affect the efficacy of neuraminidase inhibitors (NAIs). It is a recommendation by regulatory authorities to monitor for resistance during the development of anti-influenza medications. An additional requirement by regulators is to examine amino acid sequences for minority species harbouring resistance substitutions. In a Phase III study of intravenous (IV) zanamivir respiratory samples were analysed for the presence of resistant quasi species using Next Generation Sequencing (NGS). In this study ten resistance substitutions, two of which were treatment emergent, were detected by NGS that otherwise would not have been detectable by Sanger sequencing. None of the substitutions were present at any other timepoints analysed. The effect these mutations have on clinical response is difficult to characterize; in fact, all patients from which these variants were isolated had a successful clinical outcome and the effect on clinical response was therefore likely minimal. Although NGS is becoming a routine method for nucleic acid sequencing and will detect substitutions previously undetected by Sanger sequencing, the value of this technique in identifying minority species with resistance substitutions that are clinically meaningful remains to be demonstrated, particularly with acute infections such as influenza.
Keywords: influenza; intravenous zanamivir; oseltamivir.
. 2023 Jan 3;199039.
doi: 10.1016/j.virusres.2023.199039. Online ahead of print.
Lessons from resistance analysis in clinical trials of IV zanamivir
Phillip J Yates[SUP] 1 [/SUP], Nalini Mehta[SUP] 2 [/SUP], Helen A Watson[SUP] 3 [/SUP], Amanda F Peppercorn[SUP] 4 [/SUP]
Affiliations
- PMID: 36610656
- DOI: 10.1016/j.virusres.2023.199039
Abstract
Influenza infection causes substantial morbidity and mortality during seasonal epidemics and pandemics. Antivirals, including neuraminidase inhibitors, play an important role in the treatment of severely ill patients infected with influenza. Resistance is a key factor that can affect the efficacy of neuraminidase inhibitors (NAIs). It is a recommendation by regulatory authorities to monitor for resistance during the development of anti-influenza medications. An additional requirement by regulators is to examine amino acid sequences for minority species harbouring resistance substitutions. In a Phase III study of intravenous (IV) zanamivir respiratory samples were analysed for the presence of resistant quasi species using Next Generation Sequencing (NGS). In this study ten resistance substitutions, two of which were treatment emergent, were detected by NGS that otherwise would not have been detectable by Sanger sequencing. None of the substitutions were present at any other timepoints analysed. The effect these mutations have on clinical response is difficult to characterize; in fact, all patients from which these variants were isolated had a successful clinical outcome and the effect on clinical response was therefore likely minimal. Although NGS is becoming a routine method for nucleic acid sequencing and will detect substitutions previously undetected by Sanger sequencing, the value of this technique in identifying minority species with resistance substitutions that are clinically meaningful remains to be demonstrated, particularly with acute infections such as influenza.
Keywords: influenza; intravenous zanamivir; oseltamivir.